NCT07490639Completed
Family-Supported Palliative Care in Advanced Lung Cancer
Study on the Impact of Family-Supported Palliative Care on Decision-Making Experience, Mental Attitude, and Quality of Life in Patients With Advanced Lung Cancer
Source: ClinicalTrials.gov · Last updated 24 Mar 2026
Brief summary (registry, in English)
This study aims to evaluate the clinical effectiveness and ethical implications of a family-supported palliative care model in patients with advanced lung cancer. A single-center, parallel-group randomized controlled trial was conducted, in which 110 eligible patients were randomly assigned to either a routine nursing care group or a family-supported palliative care group for an 8-week intervention period. The intervention integrates structured family involvement, palliative care education, shared decision-making support, psychological counseling, symptom management, and nutritional guidance. The primary outcome is quality of life assessed by the Functional Assessment of Cancer Therapy-Lung (FACT-L). Secondary outcomes include decisional conflict (DCS), hope level (HHI), anxiety and depression (SAS/SDS), nutritional indicators (albumin and prealbumin), and pain- and inflammation-related biomarkers (substance P, prostaglandin E2, dopamine, and C-reactive protein). This study seeks to determine whether structured family engagement can improve patient-centered outcomes, reduce decisional conflict, enhance psychological well-being, and support ethically sound shared decision-making in the context of advanced cancer care.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 110 (actual)
- First submitted
- 18 Mar 2026
- Start date
- 1 Jan 2024
- Primary completion date
- 20 Feb 2025
- Lead sponsor
- Shanxi Province Cancer Hospital
- Diseases
- Lung cancer
- NCT number
- NCT07490639
What you commit to
- Study type: Interventional
- Participants enrolled: 110
- From 1 Jan 2024 to the primary completion date, 20 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior exposure to more than one line of systemic antitumor therapy.
Other illness
- Severe cognitive impairment or diagnosed psychiatric disorders affecting compliance.
- Severe comorbid conditions (cardiac, hepatic, or renal dysfunction) with life expectancy \< 3 months.
- Conditions that may interfere with outcome assessment, such as active infection or systemic inflammatory diseases.
Who the study is looking for
- Pathologically or cytologically confirmed diagnosis of advanced lung cancer (stage III-IV or limited prognosis).
- Age ≥ 18 years.
- Receiving initial or first-line systemic treatment.
- Fully informed of the diagnosis, with normal cognitive function and ability to communicate effectively.
- Able to complete questionnaires and assessments.
- Provided written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanxi Province Cancer Hospital Coordinator of this site? Confirm its status | Taiyuan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.